Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 17, 2021

SELL
$14.36 - $20.93 $7,180 - $10,465
-500 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$18.19 - $33.25 $9,095 - $16,625
500 New
500 $10,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $82.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Logan Capital Management Inc Portfolio

Follow Logan Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Logan Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Logan Capital Management Inc with notifications on news.